GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: T3 is a PROTAC degrader that simultaneously targets alpha-synuclein (α-Syn) and tau proteins [1]. It was developed for potential to reduce pathological α-Syn and tau aggregations for application as a neurodegenerative disease therapy. The target protein warhead binds both α-Syn and tau, and the cereblon E3 ubiquitin ligase is engaged by a pomalidomide moiety.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| T3 binding affinity (Kd) for α-Syn is 470 nM [1]. The DC50 for T3-induced α-Syn degradation is 1.57 μM, and for tau degradation the DC50 is 4 μM. T3 crosses the blood-brain barrier in vivo, and promotes the clearance of α-Syn and tau from the brains of MPTP-induced Parkinson's disease model mice. T3 binding affinity (Kd) for α-Syn is 470 nM. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||